Palvella Therapeutics has obtained a U.S. patent licensed from Yale University, providing broad intellectual property protection for its QTORIN™ pitavastatin topical treatment targeting porokeratosis, including disseminated superficial actinic porokeratosis (DSAP). DSAP is a rare, premalignant genetic skin disease affecting over 50,000 diagnosed patients in the U.S. with no FDA-approved therapies. The patent protects the use of topical statins like pitavastatin for this condition until 2043. Palvella plans to start a Phase 2 clinical trial for QTORIN™ pitavastatin in DSAP in the second half of 2026, aiming to offer the first targeted therapy for this serious skin disease.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
